Denali Therapeutics Inc（DNLI）財務資料DNLIDenali Therapeutics Inc

Evaluating the bottom line, Denali Therapeutics Inc. maintains a gross margin of 76.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3622.11%, while the net margin is -3539.21%. These profitability ratios, combined with a Return on Equity (ROE) of -54.93%, provide a clear picture of how effectively DNLI converts its operational activities into shareholder value.

In the context of the broader market, DNLI competes directly with industry leaders such as RCUS and DYN. With a market capitalization of $3.11B, it holds a significant position in the sector. When comparing efficiency, DNLI's gross margin of 76.61% stands against RCUS's 100.00% and DYN's N/A. Such benchmarking helps identify whether Denali Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Denali's Q2 2026 revenue was $3.6 million, exceeding expectations, while the gross margin was notably high at 76.61%. However, the company continues to report substantial net losses, with a net income of -127.55 million USD for Q2 2026.